I-Mab’s Promising Clinical Developments and Financial Stability Earn ‘Buy’ Rating from Analyst

Analyst Gil Blum from Needham maintained a Buy rating on I-MAB (IMAB – Research Report) and keeping the price target at $4.00.

Gil Blum has given his Buy rating due to a combination of factors including I-Mab’s promising clinical developments and financial stability. The company reported its first-quarter financial results for 2025, highlighting the upcoming presentation of dose escalation data for its combination therapy involving givastomig, nivolumab, and chemotherapy. This data will be showcased at the ESMO GI meeting, and there is anticipation for it to show significant improvement over existing treatments.
Additionally, I-Mab’s progress in clinical trials, particularly the early completion of enrollment in the givastomig expansion cohort, demonstrates strong momentum in its research efforts. The ongoing development of other treatments like uliledlimab and ragistomig through partnerships further strengthens its pipeline. Financially, I-Mab is well-positioned with $169 million in cash, providing a runway into 2027, which supports the company’s ability to continue its research and development activities effectively.

According to TipRanks, Blum is an analyst with an average return of -13.7% and a 30.43% success rate. Blum covers the Healthcare sector, focusing on stocks such as Sarepta Therapeutics, Autolus Therapeutics, and Immunocore Holdings.